Standard BioTools (NASDAQ:LAB - Get Free Report) will announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Standard BioTools has set its FY 2024 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.
Standard BioTools (NASDAQ:LAB - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $37.21 million during the quarter, compared to analysts' expectations of $48.15 million. Standard BioTools had a negative net margin of 87.05% and a negative return on equity of 43.45%. On average, analysts expect Standard BioTools to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Standard BioTools Price Performance
Shares of NASDAQ LAB traded down $0.06 during midday trading on Wednesday, hitting $1.78. 2,417,292 shares of the company's stock were exchanged, compared to its average volume of 2,444,302. Standard BioTools has a twelve month low of $1.21 and a twelve month high of $3.04. The firm has a market cap of $659.35 million, a P/E ratio of -1.76 and a beta of 1.58. The stock's 50 day moving average price is $1.94 and its 200-day moving average price is $2.14.
Insider Activity at Standard BioTools
In related news, Director Casdin Partners Master Fund, L purchased 1,000,000 shares of Standard BioTools stock in a transaction that occurred on Friday, August 2nd. The shares were acquired at an average price of $1.63 per share, for a total transaction of $1,630,000.00. Following the transaction, the director now directly owns 47,730,821 shares in the company, valued at approximately $77,801,238.23. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders bought 5,117,508 shares of company stock valued at $8,662,080 in the last ninety days. Insiders own 53.10% of the company's stock.
Analyst Ratings Changes
Separately, TD Cowen lowered their price objective on shares of Standard BioTools from $3.50 to $2.75 and set a "buy" rating on the stock in a research report on Thursday, August 1st.
Check Out Our Latest Stock Report on Standard BioTools
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
